FDA approves Alcon's Simbrinza for glaucoma and ocular hypertension

04/22/2013 | RTT News

Novartis unit Alcon obtained approval from the FDA to market Simbrinza Suspension, a fixed-dose combination of Brinzolamide and Brimonidine Tartrate, for the reduction of elevated intraocular pressure in patients suffering from primary open-angle glaucoma or ocular hypertension. The approval makes Simbrinza the first fixed-dose glaucoma combo treatment in the U.S. that doesn't contain a beta blocker.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI